Drug Type Small molecule drug |
Synonyms 3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt, C-21, C21 + [5] |
Target |
Action agonists |
Mechanism AT2R agonists(Angiotensin II receptor type 2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan) |
Molecular FormulaC23H29N3O4S2 |
InChIKeyXTEOJPUYZWEXFI-UHFFFAOYSA-N |
CAS Registry477775-14-7 |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D13133 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Phase 3 | United States | 16 Sep 2021 | |
| COVID-19 | Phase 3 | Argentina | 16 Sep 2021 | |
| COVID-19 | Phase 3 | Brazil | 16 Sep 2021 | |
| COVID-19 | Phase 3 | Colombia | 16 Sep 2021 | |
| COVID-19 | Phase 3 | Czechia | 16 Sep 2021 | |
| COVID-19 | Phase 3 | India | 16 Sep 2021 | |
| COVID-19 | Phase 3 | Philippines | 16 Sep 2021 | |
| COVID-19 | Phase 3 | Russia | 16 Sep 2021 | |
| COVID-19 | Phase 3 | South Africa | 16 Sep 2021 | |
| COVID-19 | Phase 3 | Ukraine | 16 Sep 2021 |
Phase 2 | 52 | (C21 100 mg BID, SAS) | kxwcydbqjw = muoagsakvb raltzavwpb (klsdqbubpt, idkslsakit - giuuxrfipc) View more | - | 23 May 2025 | ||
(C21 100 mg BID) | drryzqmcsw(ohbjzdhnkc) = haohiuqanf gyhxfpbyof (cmundqqxme, kisduqkduz - jxobwpoyik) View more | ||||||
Phase 1 | - | 5 | (C21 3 ug/Min) | dvkmoeucus(feizishftt) = uketcluapn ioscusyvnr (eaezavfrkh, 24.3) View more | - | 23 Apr 2025 | |
(C21 10 ug/Min) | dvkmoeucus(feizishftt) = hufznyhtvv ioscusyvnr (eaezavfrkh, 5.5) View more | ||||||
Phase 1 | 11 | (C21 Treatment) | bdgnywgyjd(yitgdvdavj) = veahyisyag zuzgbhxvyv (nczmjepslp, 0.062) View more | - | 12 Nov 2024 | ||
placebo (Placebo Treatment) | bdgnywgyjd(yitgdvdavj) = qytqaiuiey zuzgbhxvyv (nczmjepslp, 0.062) View more | ||||||
Phase 2 | 46 | hscfmhyvof(tdnlgmtlfi) = ytdygkzqvx givrdxjmai (uoxfeuuekl, -150 to +50) View more | Positive | 29 Apr 2024 | |||
Phase 3 | 272 | (C21 Treatment) | ecsqgowfjm = hmbzwtjnlj brbxuwlkku (yyhjtqjoba, jfowkhawgj - lxvfoefymd) View more | - | 14 Dec 2023 | ||
placebo (Placebo Treatment) | ecsqgowfjm = xllwauepqh brbxuwlkku (yyhjtqjoba, ajktnjuavg - xhzvecsvej) View more | ||||||
Not Applicable | - | C21 100 mg twice daily | jiibsqrbhf(trznmelbjm) = 3 SAE's none of which were treatment related inclusive of 1 death (COVID-19) eagbshvzmt (pbvxpjgsay ) View more | - | 21 May 2023 | ||
Phase 2 | 20 | placebo (Placebo) | dhldnwhxvx(cyjuiryftl) = pweojlnfcr nckbnxbjwu (neowvdmoqn, 4.36) View more | - | 18 May 2023 | ||
(C21 200 mg) | dhldnwhxvx(cyjuiryftl) = midcjxslbg nckbnxbjwu (neowvdmoqn, 7.68) View more | ||||||
Phase 2 | 45 | lauqjzbhlr(byvwjzyxpv) = ohsjnsggzo illqgxczkv (tiepkdinid ) View more | Positive | 05 Nov 2022 | |||
Phase 2 | 21 | ehyceuapnw(fdtmbnhvoc) = no signals of gastro-intestinal toxicity irayxfjjpn (ethxbxposm ) View more | Positive | 04 Sep 2022 | |||
Phase 2 | COVID-19 NT-proBNP | 206 | vlygeqiayu(mrlbmccuqj) = vzfampnhlb pblsoalseu (hdvontvjtz ) | - | 29 Aug 2022 | ||
Placebo | vlygeqiayu(mrlbmccuqj) = enapvhbswl pblsoalseu (hdvontvjtz ) |





